title: Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis.
abstract: Plaque-type palmoplantar psoriasis (PPP) is associated with marked morbidity and frequently resistant to conventional therapies. Patients with long-standing plaque-type PPP failing previous treatments were included and treated with a 12-week intramuscular alefacept. The biweekly evaluation included hyperkeratosis, itching, and pain grading. In all of the seven treated patients significant to complete improvement in hyperkeratosis, pruritus and pain were observed, along with dose reduction or complete discontinuation of additional systemic treatments and without any recorded side effects. Alefacept should be considered as a therapeutic option for plaque-type PPP.
authors.affiliation: Dermatology Day Care and Phototherapy Center, Sheba Medical Center, Tel Hashomer and Dermatology Clinic, Tel Nordau Medical Center, Tel Aviv, Israel. lior115@gmail.com
authors.forename: Sagi
authors.initials: S
authors.lastname: Lior
authors.forename: Kriger
authors.initials: K
authors.lastname: Grigory
authors.forename: Shemesh
authors.initials: S
authors.lastname: Pnina
authors.forename: Shiri
authors.initials: S
authors.lastname: Joseph
authors.forename: Pavlotsky
authors.initials: P
authors.lastname: Felix
mesh_terms: D000328:Adult; D000368:Aged; D000077944:Alefacept; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007642:Keratosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D011993:Recombinant Fusion Proteins; D000077944:Alefacept